Updated:
CorMedix
CorMedix, led by CEO Joseph Todisco, secured FDA approval for the catheter lock solution DefenCath in 2023 and began its U.S. commercial launch in 2024.
CorMedix
CorMedix was founded in 2006 and reincorporated in Delaware in 2013, with Joseph Todisco appointed CEO in 2016. The company is a publicly traded biopharmaceutical entity (Nasdaq: CRMD) rather than a private family office or investment fund. Its wealth origin is tied to public equity markets. The firm's headquarters are in Berkeley Heights, New Jersey. The company's strategy centers on the development and commercialization of therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its sole commercial asset is DefenCath (taurolidine and heparin), a proprietary antimicrobial catheter lock solution. In November 2023, the FDA approved DefenCath to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis via a central venous catheter. The product was launched commercially in the inpatient setting during April 2024, and an outpatient launch followed in July 2024 (per the firm's public SEC filings, 2024). The geographic focus is currently the United States. Scale is measured in market authorization and quarterly revenue rather than traditional assets under management. As a small-cap, pre-profitability biotech, the team is lean and led by CEO Joseph Todisco and CFO Matt David. In May 2024, the Centers for Medicare & Medicaid Services granted a Transitional Drug Add-on Payment for DefenCath, providing additional reimbursement for the product in the hospital outpatient setting (per the firm's public disclosures, May 2024). The company maintains a strategic focus on intellectual property to protect its position, holding patents on its taurolidine-based formulations. CorMedix differs structurally from a diversified investment fund; it is an operating company. Its architecture as a single-product, single-market biotech concentrates its enterprise value almost entirely on the commercial ramp of DefenCath. The firm's path is defined by manufacturing partners, a focused sales force, and the reimbursement landscape for dialysis service providers.
General information
Firm type
Asset Manager
Year founded
2006
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Berkeley Heights
Corporate office
Berkeley Heights, NJ, United States
Principals
Joseph Todisco
Chief Executive Officer
Matt David
Chief Financial Officer
Sector focus
Frequently asked questions
What is CorMedix's primary revenue-generating product?
CorMedix's primary product is DefenCath, a combination of taurolidine and heparin approved as a catheter lock solution. It targets the reduction of catheter-related bloodstream infections in adult patients with kidney failure who are receiving chronic hemodialysis. The FDA approved DefenCath in November 2023, and the company began commercial sales in the first half of 2024.
Who makes the key investment and operational decisions at CorMedix?
Joseph Todisco has served as Chief Executive Officer since 2016 and leads commercial strategy and operations. The company is overseen by a Board of Directors and governed by an independent audit committee as required by Nasdaq listing standards. Major financial decisions are executed by the C-suite team, which includes CFO Matt David.
What was the significance of the FDA approval in November 2023?
The FDA approval of DefenCath in November 2023 allowed CorMedix to transition from a development-stage company to a commercial-stage biotech. The approval provided a specific indication for reducing bloodstream infections in a high-risk hemodialysis population. This regulatory milestone triggered the buildout of a U.S. commercial sales force.
How does CorMedix generate capital given it has no disclosed assets under management?
CorMedix is a publicly traded company and raises capital through the equity markets rather than managing external client funds. The firm has historically funded operations through public offerings and registered direct placements of common stock. As product revenue from DefenCath grows, the company aims to transition toward self-sustaining operational cash flow.
Where are CorMedix's therapeutic products sold?
CorMedix currently focuses its commercialization efforts exclusively on the United States. The initial market is concentrated in hemodialysis centers, with the product billing structure depending on whether the patient receives treatment in a hospital inpatient, hospital outpatient, or freestanding dialysis clinic setting. No international sales have been announced.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: